Scarica l'app Stockscreener
197.93
2.17%
4.21
Dopo l'orario di chiusura:
198.35
0.42
+0.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DHR Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$193.72
Aprire:
$197.47
Volume 24 ore:
3.99M
Relative Volume:
0.88
Capitalizzazione di mercato:
$140.09B
Reddito:
$24.78B
Utile/perdita netta:
$3.68B
Rapporto P/E:
38.25
EPS:
5.1743
Flusso di cassa netto:
$5.29B
1 W Prestazione:
+2.44%
1M Prestazione:
+12.39%
6M Prestazione:
-14.09%
1 anno Prestazione:
-2.26%
Intervallo 1D:
$194.47
$198.23
Intervallo di 1 settimana:
$188.99
$198.23
Portata 52W:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Nome
Danaher Corp
Settore
Industria
Telefono
(202) 828-0850
Indirizzo
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, IDXX, NTRA, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
197.93 | 134.82B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
523.44 | 186.32B | 45.20B | 6.87B | 6.75B | 18.19 |
IDXX
Idexx Laboratories Inc
|
557.80 | 41.53B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
279.32 | 38.88B | 2.50B | -226.32M | 71.51M | -1.6412 |
WAT
Waters Corp
|
379.29 | 36.82B | 3.77B | 449.25M | 240.68M | 7.8556 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Goldman | Buy |
| 2025-12-02 | Iniziato | Morgan Stanley | Overweight |
| 2025-10-08 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-03-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-03-14 | Aggiornamento | Stifel | Hold → Buy |
| 2025-02-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-19 | Iniziato | Guggenheim | Buy |
| 2024-12-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-31 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-18 | Iniziato | HSBC Securities | Hold |
| 2023-12-13 | Ripresa | Wolfe Research | Peer Perform |
| 2023-12-07 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-05-01 | Iniziato | SVB Securities | Outperform |
| 2023-04-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-10-24 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-17 | Ripresa | Bernstein | Outperform |
| 2022-07-20 | Iniziato | UBS | Buy |
| 2022-06-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | Iniziato | Bernstein | Outperform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-10 | Reiterato | BofA Securities | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-23 | Reiterato | Goldman | Buy |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-04-07 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-03 | Ripresa | Barclays | Overweight |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | Reiterato | Needham | Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Ripresa | Stifel | Hold |
| 2019-10-28 | Reiterato | Needham | Buy |
| 2019-10-14 | Ripresa | Credit Suisse | Outperform |
| 2019-07-19 | Reiterato | Needham | Buy |
| 2019-06-11 | Iniziato | Piper Jaffray | Neutral |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-04-17 | Reiterato | Needham | Buy |
| 2019-02-28 | Reiterato | Needham | Buy |
| 2019-02-25 | Aggiornamento | Janney | Neutral → Buy |
| 2019-01-03 | Iniziato | Needham | Buy |
| 2018-04-20 | Reiterato | Stifel | Buy |
Mostra tutto
Danaher Corp Borsa (DHR) Ultime notizie
Danaher Corp. focuses on diversified science tools as investors weigh long term growth - AD HOC NEWS
Danaher Corp adjusts guidance after Masimo deal. Analysts highlight cautious upside for the stock - AD HOC NEWS
Spatial Genomics and Transcriptomics Market Size to Reach USD 1.90 Billion by 2035, Growing at a 12.23% CAGR | SNS Insider - GlobeNewswire Inc.
DHRDanaher Corp Latest SEC Filings - Finviz
Deals tracker: Select Medical Holdings acquisition moves forward - Modern Healthcare
Danaher Corp. stock underperforms Monday when compared to competitors - MarketWatch
$1M Danaher grant targets Ebola outbreak in Congo, Uganda - Stock Titan
Danaher (DHR) Completes $9.9B Acquisition of Masimo Corporation - Insider Monkey
Is Danaher (DHR) One of the Best Non-Tech Stocks to Buy According to Analysts? - Insider Monkey
Danaher schedules Q2 earnings call, analysts reassess the shares - Ad-hoc-news.de
Danaher schedules Q2 earnings call, shares steady in S&P 500 - Ad-hoc-news.de
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
Danaher boosts product portfolio with the acquisition of Masimo - MSN
Danaher clears new AI milestone with Masimo, shares react on NYSE - Ad-hoc-news.de
Danaher Corp Shs Unsponsored Brazilian Depository Receipt Repr 0.035714285 Sh - TradingView
Danaher Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
DHR Forecast — Price Target — Prediction for 2027 - TradingView
Danaher (DHR) Stock Weighs Mixed Valuation Signals After Recent Price Rebound - Yahoo Finance
Why Danaher (DHR) Stock Rose Today - Quiver Quantitative
Danaher clears FDA hurdle with Masimo, shares extend rebound on NYSE - Ad-hoc-news.de
Danaher (DHR) Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance
Why Is (NYSE:DHR) Back in Focus Following AI Monitoring Approval? - Kalkine Media
Danaher $172.5 Million Securities Class Action Settlement - Claim Depot
Is Danaher (DHR) Using Masimo’s New FDA-Cleared AI Tool To Redefine Its Medtech Edge? - Yahoo Finance
A Look at Danaher Corp (DHR) After 5.5% Gain -- GF Value $236.97 vs Price $188.87 - GuruFocus
Danaher Corp Stock (DHR) Moved Up by 4.91% on Jun 24: What Investors Need To Know - TradingKey
HSBC Cuts PT on Danaher Corporation (DHR) – Here’s Why - Insider Monkey
How FDA Clearance of AI Opioid-Respiratory Monitoring Could Shape Danaher’s (DHR) Clinical Data Advantage - simplywall.st
Danaher achieves FDA clearance for Masimo feature, shares steady on NYSE - Ad-hoc-news.de
Danaher Corp (DHR) Institutional Confidence - TradingKey
Danaher plans July 21 earnings call, slide deck at 6 a.m. ET - Stock Titan
Danaher Finalizes $9.9B Purchase of Masimo - Orange County Business Journal
Danaher (DHR) Achieves FDA Clearance for Wearable Monitoring Tec - GuruFocus
Danaher Schedules Second Quarter 2026 Earnings Conference Call - Yahoo Finance
Danaher Stockweekly outlook with earnings and events ahead - Ad-hoc-news.de
Medtech business update: Spectrum Vascular acquires Piccolo Medical, Danaher acquires Masimo - Today's Medical Developments
From bench chaos to calm order, Cytiva ÄKTA pure quietly cleans up protein prep - AD HOC NEWS
Lodi's largest private employer expands with fifth building - The Business Journals
Danaher Corp (DHR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Danaher Corp (DHR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Danaher Corp (DHR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Danaher Corp (DHR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Danaher Corp. stock outperforms competitors despite losses on the day - MarketWatch
Danaher Corp (DHR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Danaher Corp (DHR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Danaher Corp (DHR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IDBS and Alchemi partner to accelerate biopharma regulatory filings with compliant AI agents - PR Newswire
Danaher’s Cepheid Ebola Tests Highlight Diagnostics Role In Global Crises - Yahoo! Finance Canada
Masimo CEO stepping down following acquisition by Danaher - Modern Healthcare
Danaher Corporation’s (DHR) Recovery Fell Short of Investor Expectations - Yahoo Finance
Danaher Corp Azioni (DHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
2.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):